PSRC1 and hepatocellular carcinoma: Overall, the evidence reported here points out PSRC1 as a possible novel target for HCC and the chr1p3.13 variation as a potentially useful marker to be incorporated in polygenic risk scores to differentiate the risk of progressive liver disease from that of cardiovascular events in individuals with dysmetabolism [54].